Drug Profile
ARC 031
Alternative Names: ARC 031SR; ARC031Latest Information Update: 21 Mar 2016
Price :
$50
*
At a glance
- Originator Archer Pharmaceuticals
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 Mar 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (PO, controlled-release)
- 21 Mar 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (PO, immediate-release)
- 02 Mar 2010 Phase-I clinical trials in Alzheimer's disease in USA (PO, controlled-release)